EIF2AK4

Across TCGA pan-cancer cohorts, EIF2AK4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EIF2AK4 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF2AK4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF2AK4 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where EIF2AK4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.565	0.903	.006	22	view →
CCRCC	OS	Median	IV	0.123	0.785	.009	21	view →
LSCC	OS	Tertile	III,IV	0.391	0.879	.003	12	view →
LUAD	OS	Quartile	All	0.944	0.577	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EIF2AK4–PDAC (DFS)

Open the PDAC breakdown →